1. Introduction {#sec1}
===============

Left ventricular hypertrophy (LVH) is an important factor in the occurrence of cardiac remodeling and cardiovascular events \[[@B1]\]. Diabetes is a risk factor of LVH, which is independent of hypertension \[[@B2]\]. Because of the high prevalence of hypertension in diabetes and its effect on cardiac structure independently of primary diseases \[[@B3]\], LVH has a high prevalence in diabetes. A previous study reported that about 70% of patients with type 2 diabetes mellitus (T2DM) had LVH \[[@B4]\]. It is even a stronger predictor of cardiovascular events than triple vessel coronary disease \[[@B5], [@B6]\]. One possible reason is that LVH is an early event in the development of arrhythmia, diastolic heart failure, ischemia, and atrial fibrillation \[[@B7]\]. Both electrocardiograph and echocardiography can be used in LVH diagnosis, but the former has a low sensitivity and it is expensive to screen for LVH in all patients with diabetes with the latter. In China, with the increasing prevalence of T2DM from 0.67% in 1980 to 10.4% in 2013 \[[@B8]\], it would be unrealistic to perform echocardiographic examination for all T2DM. Therefore, it is necessary to identify a sensitive and simple enough marker for LVH in T2DM, which can be used for risk stratification, especially in primary care.

Several mechanisms such as endothelial dysfunction, insulin resistance, and accelerated accumulation of advanced glycation end products (AGEs) have been proposed in order to explain the existing relationship between diabetes and LVH. The Steno hypothesis believes that albuminuria reflects widespread endothelial dysfunction, not only renal function impairment \[[@B9]\]. It has been reported that certain urinary proteins play a significant role in other systemic diseases, not just in urogenital diseases \[[@B10]--[@B12]\]. Urinary albumin/creatinine ratio (UACR) in a random spot urine is the easiest method to screen for albuminuria. Normal UACR is generally defined as \<30 mg/g, used for kidney damage screening in patients with diabetes \[[@B13]\]. Despite robust evidence of the relationship between abnormal UACR and LVH in patients with diabetes, it is known that even a level of UACR below 30 mg/g increases the risk of cardiovascular diseases (CVDs). Recent studies have demonstrated that normal UACR is associated with an elevated risk of CVD mortality and incident hypertension, but not incident diabetes, which indicated that a higher level of UACR might be provoked by endothelial dysfunction, rather than a causal factor \[[@B14]\].

Based on these findings, we speculate that even if UACR is in the normal range, an altered level of UACR is associated with LVH prevalence. Therefore, we conduct a cross-sectional study to investigate the relationship between UACR below 30 mg/g and LVH in patients with diabetes.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

This is a retrospective study. Records of consecutively admitted patients between June 2016 and June 2018 to Nanfang Hospital, Southern Medical University, for evaluation or treatment of T2DM were reviewed. Patients with any of following conditions were excluded: (1) \<18 years old; (2) congenital heart disease or primary pulmonary arterial hypertension; (3) urinary albumin/creatinine ratio (UACR) ≥30 mg/g; (4) a history of known coronary heart disease, coronary artery bypass or angioplasty, and severe valvular heart disease; and (5) concurring pregnancy or infection. For those with several hospitalizations, only records from the first hospitalization were included. The study was approved by the institutional review board of Nanfang Hospital. No informed consent was required because the data in our study were anonymized.

2.2. Data Collection {#sec2.2}
--------------------

All demographic characteristics were obtained from electronic medical records of Nanfang Hospital including age, gender, weight, height, body mass index (BMI), smoking, duration of diabetes, medication history, systolic blood pressure (SBP), diastolic blood index (DBP), and comorbidities. The blood samples were taken after fasting for 12 h overnight, and the first morning urine samples were collected within 24 h of admission. Hemoglobin (HGB), hematocrit (HCT), total cholesterol (CHOL), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglyceride (TG), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), fasting insulin (FINS), albumin (ALB), serum creatinine (Cr), urine acid (UA), urea nitrogen (UREA), phosphate, sodium, and chlorine were all collected from hospital database. Urine albumin was measured by immunoturbidimetric assay, and urinary creatinine concentration was measured by enzymatic method. As recommended by the American Society of Echocardiography \[[@B15]\], transthoracic echocardiography was performed by a senior echocardiographer. Color Doppler ultrasonic diagnostic apparatus by German Siemens Company (Siemens Sequoia 512 Encompass) was used for the examination, with patients in partial left lateral decubitus position. Bilateral carotid ultrasonography was performed according to standards for carotid ultrasound examination in Chinese healthy population \[[@B16]\].

2.3. Definition of Covariates {#sec2.3}
-----------------------------

Anemia was defined according to the Chinese Society of Hematology expert consensus on iron deficiency anemia as HGB \< 120 g/L for men and HGB \< 110 g/L for women \[[@B17]\]. Obesity was defined as BMI ≥ 28 kg/m^2^ according to the Chinese standard \[[@B18]\]. Smoking was defined as "ever smoked." The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation \[[@B19]\]. Insulin resistance was estimated by the homeostatic model: HOMA-IR = FPG (mmol/L) × FINS (mIU/L)/22.5 \[[@B20]\]. According to the European Association of Cardiovascular Imaging and the American Society of Echocardiography \[[@B21]\], relative wall thickness (RWT) was calculated as the ratio of two times posterior wall thickness to end-diastolic left ventricular (LV) diameter and increased RWT was defined as \>0.42. Left ventricular mass (LVM) was estimated according to the formula: LVM (*g*) = 0.8 × 1.04 × \[(LVIDd (cm) + LVPWd + IVSd)^3^ − LVIDd^3^\] + 0.6. Normalization of LVM for height to the power of 2.7 was regarded as the left ventricular mass index (LVMI). LVH was defined as follows: LVMI \> 48 g/m^2.7^ for men and LVMI \> 44 g/m^2.7^ for women. LV geometry was defined as normal (normal LVMI and normal RWT); concentric remodeling (normal LVMI and increased RWT); eccentric hypertrophy (increased LVMI and normal RWT); and concentric hypertrophy (increased LVMI and increased RWT).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Normally distributed continuous variables were expressed as the mean value ± standard deviation, while nonnormally distributed variables were expressed as the median with interquartile ranges. Differences in normally distributed variables were determined by independent-sample *T* test or one-way ANOVA or Kruskal--Wallis tests. Homogeneity of variance was explored by the Levene test, and a *P* value less than 0.1 was considered heterogeneity of variance. Nonparametric test was used for comparing the difference of nonnormally distributed variables. Categorical variables were reported as numbers and percentages, and chi-square test was used for comparing proportions. Multivariable linear regression analysis was applied to explore an independent association between UACR and other clinical parameters. UACR was logarithmically transformed to approximate normal distribution. The ability to differentiate LVH of UACR was evaluated using the area under the curve (AUC) in the receiver operating characteristic (ROC) curve. Multivariable logistic regression analysis was used for determining the variables associated with LVH and identifying the association between LVH and UACR. A two-sided *P* value of \<0.05 was considered statistically significant. All analyses were performed using SPSS version 22.0 (IBM SPSS Statistics, IBM Corporation, Armonk, New York).

3. Results {#sec3}
==========

3.1. Clinical Characteristics {#sec3.1}
-----------------------------

In our study, 534 patients were enrolled, and after exclusion, a total of 317 patients were included in the statistical analysis ([Figure 1](#fig1){ref-type="fig"}); 39.4% were female, with a mean age of 55.2 ± 12.1 years. The median duration of diabetes was 6 (1--10) years. LVH, hypertension, carotid plaque, atrial fibrillation (AF), obesity, and anemia were presented in 62 (19.6%), 119 (37.5%), 50 (15.8%), 3 (0.9%), 47 (14.8%), and 29 (9.1%) patients, respectively. Patients\' characteristics in subjects with non-LVH and in those with LVH are shown in [Table 1](#tab1){ref-type="table"}.

Significant difference in UACR was observed between non-LVH and LVH groups (6.2 (4.4--10.6) vs. 11.5 (6.0--21.2) mg/g, *P* \< 0.001). Patients with LVH tended to have higher percentage of the subjects with hypertension, obesity, and the use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) and calcium channel blocker (CCB), be older, and fewer were males. Laboratory values such as HbA1c, FPG, HOMA-IR, and eGFR did not demonstrate any statistically significant difference between the two groups.

Patients\' characteristics in subjects categorized by UACR quartiles are listed in [Table 2](#tab2){ref-type="table"}. From UACR quartile 1 to quartile 4, the prevalence of LVH significantly rose from 10.8% to 36.7% (*P* \< 0.001). There was a significant increase in the usage rate of ACEI/ARB and HbA1c and a significant decrease in ALB across UACR quartiles. Nevertheless, there was a remarkably similar usage rate of CCB and eGFR across UACR quartiles.

3.2. Association with the UACR Levels {#sec3.2}
-------------------------------------

We performed single regression and multiple regression analysis between HbA1c, ALB, age, gender, hypertension, smoking, the use of ACEI or ARB medication, and log~2~ UACR levels ([Table 3](#tab3){ref-type="table"}). There was a significantly negative correlation between the log~2~ UACR levels and ALB (*P*=0.003), while significantly positive correlation was observed between log~2~ UACR and HbA1c (*P* \< 0.001), independent of hypertension, the use of ACEI or ARB medication, smoking, age, and gender.

3.3. Association with LVH {#sec3.3}
-------------------------

To investigate the variables associated with LVH, we performed backward stepwise multinomial logistic regression analysis to include gender, age, hypertension, duration of diabetes, smoking, ALB, obesity, SBP, HDL-c, eGFR, log~2~ HOMA-IR, carotid plaque, log~2~ UACR, the use of ACEI or ARB, CCB, and statin medication on first step, which indicated that LVH was independently associated with gender, age, hypertension, obesity, and log~2~ UACR ([Table 4](#tab4){ref-type="table"}).

The receiver operating characteristic (ROC) curve to differentiate patients with LVH yielded an area under the curve (AUC) of 0.682 (95% CI: 0.602--0.760, *P* \< 0.001) for UACR ([Figure 2](#fig2){ref-type="fig"}). An optimal cutoff value for UACR of 10.2 mg/g for LVH was determined with the Youden index. Sensitivity, specificity, positive predictive value, and negative predictive value, respectively, were 61.3%, 74.9%, 75.2%, and 88.8%.

The ORs (95% CI) for LVH according to changes in UACR levels were shown by logistic regression analysis when UACR is a categorical variable (an optimal cutoff value according to the maximum Youden index) or a continuous variable (log~2~ UACR) ([Table 5](#tab5){ref-type="table"}). Compared to UACR \< 10.2 mg/g group, the OR for LVH was 3.104 (95% CI: 1.557--6.188, *P*=0.001) in UACR \> 10.2 mg/g group, after adjustment for age, gender, and obesity in model 1, further adjustment for hypertension, carotid plaque, and duration of diabetes in model 2, and furthermore adjustment for smoking, the use of ACEI/ARB, and statin medication in model 3. As a continuous variable, for every increase of 100 percent in UACR level, the OR for LVH was 1.511 (95% CI: 1.047--2.180, *P*=0.028) in the fully adjusted model.

4. Discussion {#sec4}
=============

We report here a cross-sectional study to investigate the association of UACR below 30 mg/g and left ventricular hypertrophy in patients with type 2 diabetes in South China. We found that even if UACR was in the normal range, a high UACR level was significantly associated with the prevalence of LVH, which was independent with the effect of age, gender, obesity, hypertension, carotid plaque, duration of diabetes, smoking, the use of ACEI/ARB, and statin medication.

In fact, there are many studies demonstrating that a high level of UACR is associated with an increased risk of cardiovascular diseases such as ischemic electrocardiographic abnormalities \[[@B22]\], coronary artery calcification score, and carotid intima-media thickness \[[@B23]\] in nondiabetic patients or diabetic patients. LIFE study discovered that increased UACR contributed to increasing risk of cardiovascular events without thresholds or plateaus \[[@B24]\]. In 2013, Gutiérrea et al reported that the effect of UACR on cardiovascular outcomes differed by race, with nonwhite being more susceptible than whites \[[@B25]\]. In 2017, Siddique et al. demonstrated that mildly increased UACR (10 mg/g−30 mg/g) was associated with a 1.4 times increase in all-cause mortality (*P*=0.042) in 2176 patients with diabetes with coronary heart disease by a post hoc analysis of BARL-2D study \[[@B26]\]. However, they did not investigate the relationships between the changes of heart structure and a mildly elevated UACR (\<30 mg/g) in T2DM. We cannot know the reason why mildly elevated UACR increases the risk of cardiovascular events.

Previous studies have demonstrated an absolute association between T2DM and LVH \[[@B2], [@B27], [@B28]\]. T2DM is a significant trigger for endothelium damage, myocardial infarction, and heart failure. Traditional factor such as blood pressure can only explain about 25% of the variability in left ventricular mass \[[@B29]\]. ACEI/ARB use can reduce the risk of LVH but not cure it \[[@B4]\]. On the other hand, LVH is one of the clinical manifestations of diabetic cardiomyopathy \[[@B30], [@B31]\]. Considering the relationships between these diseases, it is significantly important to make an early diagnosis of LVH in T2DM.

In this study, we find that existing LVH may be invoked to explain the relationships between a mildly elevated UACR (\<30 mg/g) and the risk of cardiovascular events. Our results suggested that 10 mg/g is the optimal cutoff points for identifying LVH in T2DM. Although Somaratne et al. also investigated the value of serum NT-proBNP to screen for LVH in T2DM, the results showed that serum NT-proBNP was unsuitable for a screening tool because of the influence of obesity or other metabolic risk factors \[[@B32]\]. The detection of UACR is less burdensome than timed or 24 h collections, bringing patients a lot of convenience. Measurement of UACR level has been general for T2DM, but UACR below 30 mg/g is often ignored. As we know, based on screening for renal damage, normal UACR is generally defined as \<30 mg/g. It is more appropriate if \<10 mg/g can be defined as a normal range of UACR to screen for left ventricular remodeling. Previous studies have shown that hypertension is often accompanied in patients with T2DM and can cause left ventricular diastolic dysfunction. Early echocardiography is recommended for diagnosing left ventricular diastolic dysfunction \[[@B33]\]. For the high prevalence of T2DM, UACR may also become a cheaper method for primary assessment of left ventricular structure and function. Moreover, we report that HbA1c level had a positive correlation with UACR, independent of hypertension, even in T2DM patients with a normal range of UACR, which suggested that there are some mechanisms between glycemic control and urinary albumin excretion. In our study, we did not find a significant difference between HOMA-IR and the prevalence of LVH. Previous studies have shown the considerable effect of brain natriuretic peptide (BNP) in counteracting IR. BNP can improve IR by reducing BMI via fat oxidation \[[@B34]\] or triglyceride lipolysis \[[@B35]\]. Serum NT-proBNP levels in LVH are higher than those in non-LVH \[[@B32]\], which may account for our results.

As we all know, UACR and eGFR are both biomarkers of kidney disease and both associate with systematic endothelial dysfunction. However, in our study, there is no significant difference in eGFR between the high UACR group and the low UACR group. The possible cause is that eGFR level estimated by the MDRD equation is not accurate enough, or UACR level is more sensitive for detecting subclinical renal damage than eGFR level. If these results are confirmed in further studies, UACR levels and its novel cutoff value can prove to be an economical and practical method for initial screening and follow-up of LVH in T2DM. Patients with T2DM who have more than 10 mg/g of UACR can be recommended to undergo echocardiography by experienced professionals. Since some research studies about the treatment of heart failure attach importance to the alleviation of LVH \[[@B36]\], it can be expected that the timely screening of LVH in T2DM will be paid more and more attention.

5. Limitations {#sec5}
==============

Our study had several limitations. Firstly, this is a retrospective study and the results need validation in a prospective trial. For the retrospective nature of this study, we could not get the data of repeated measurement of echocardiographic parameters. But in our study, all patients\' echocardiography was performed by the same senior echocardiographer, so the results were reliable and stable. Secondly, UACR level can change from day to day, but we only measured UACR a single time, which might result in inaccuracy of measurement. However, there are a number of evidences indicating that a single-voided test is reliable in screening for diseases \[[@B37], [@B38]\]. Finally, the insulin resistance index calculated by the homeostatic model in patients with diabetes was less accurate than in patients without diabetes, so the results were for preliminary reference only.

6. Conclusion {#sec6}
=============

In summary, this study found that a high level of UACR is associated with LVH in T2DM. The optimal cutoff value for screening for LVH in T2DM is 10 mg/g. Further investigation is necessary to better manage diabetes with mildly increased UACR (10--30 mg/g).
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###### 

Characteristics of patients grouped by left ventricular hypertrophy.

  Variables                         LVH                          *P* value                  
  --------------------------------- ---------------------------- -------------------------- ---------
  Age (years)                       53.3 ± 11.8                  63.0 ± 10.5                \<0.001
  Female, *n* (%)                   80 (31.4)                    45 (72.6)                  \<0.001
  Smoking, *n* (%)                  71 (27.8)                    6 (9.7)                    0.003
  Hypertension, *n* (%)             75 (29.4)                    44 (71.0)                  \<0.001
  Carotid plaque, *n* (%)           39 (15.3)                    11 (17.7)                  0.635
  Duration of diabetes (years)      5 (1--10)                    9 (5--13)                  0.001
  SBP (mmHg)                        132.3 ± 17.3                 139.6 ± 19.6               0.004
  DBP (mmHg)                        81.1 ± 10.3                  80.9 ± 12.3                0.925
  BMI (kg/m^2^)                     24.3 ± 3.6                   25.9 ± 5.5                 0.025
  Obesity, *n* (%)                  30 (11.8)                    17 (27.4)                  0.002
                                                                                            
  *Medication history*                                                                      
  ACEI/ARB use, *n* (%)             42 (16.5)                    27 (43.5)                  \<0.001
  Statin use, *n* (%)               102 (40.0)                   30 (48.4)                  0.230
  CCB use, *n* (%)                  24 (9.4)                     17 (27.4)                  \<0.001
  *β*-Blocker, *n* (%)              11 (4.3)                     5 (8.1)                    0.375
                                                                                            
  *Laboratory values*                                                                       
  HbA1c (%)                         8.5 (6.9--10.4)              8.9 (6.6--10.6)            0.948
  HOMA-IR                           1.45 (0.71--2.81)            1.51 (0.81--3.66)          0.457
  FPG (mmol/L)                      6.9 (5.4--8.6)               6.9 (5.8--8.6)             0.765
  Anemia, *n* (%)                   21 (8.2)                     8 (12.9)                   0.253
  CHOL (mmol/L)                     4.80 ± 1.03                  4.85 ± 1.16                0.755
  LDL-c (mmol/L)                    3.03 ± 0.83                  3.04 ± 0.90                0.877
  HDL-c (mmol/L)                    1.03 ± 0.28                  1.09 ± 0.29                0.177
  TG (mmol/L)                       1.28 (0.97--1.97)            1.44 (1.10--2.04)          0.246
  ALB (g/L)                         39.0 ± 4.3                   38.4 ± 3.8                 0.370
  P (mmol/L)                        1.27 ± 0.22                  1.23 ± 0.19                0.158
  Na (mmol/L)                       140.3 ± 3.2                  140.5 ± 2.6                0.670
  Cl (mmol/L)                       103.5 ± 3.7                  103.6 ± 3.0                0.869
  UREA (mmol/L)                     5.0 (4.2--6.0)               4.9 (4.2--6.1)             0.918
  UA (*μ*mol/L)                     349.5 ± 99.9                 337.6 ± 96.1               0.400
  eGFR (mL·min^−1^·1.73 m^−2^)      102.0 ± 27.9                 97.2 ± 33.9                0.309
  UACR (mg/g)                       6.2 (4.4--10.6)              11.5 (6.0--21.2)           \<0.001
                                                                                            
  *Echocardiography*                                                                        
  EF (%)                            67.7 ± 5.6                   67.1 ± 7.8                 0.602
  AO (mm)                           25.5 ± 3.3                   25.9 ± 3.7                 0.401
  LA (mm)                           29.9 ± 3.9                   32.1 ± 3.9                 \<0.001
  E/A                               ^a^(253) 0.82 (0.72--1.21)   \(61\) 0.70 (0.65--0.81)   \<0.001
                                                                                            
  *LV geometry*                                                                             
  Normal, *n* (%)                   72 (22.7)                    ---                        ---
  Concentric remodeling, *n* (%)    183 (57.7)                   ---                        ---
  Eccentric hypertrophy, *n* (%)    ---                          12 (3.8)                   ---
  Concentric hypertrophy, *n* (%)   ---                          50 (15.8)                  ---

SBP = systolic blood pressure; DBP = diastolic blood pressure; ACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB: calcium channel blocker; HbA1c = hemoglobin A1c; HOMA-IR = homeostasis model assessment ratio; EF = ejection fraction; AO = aortic root; LA = left atrial. ^a^The remaining valid data regardless of the missing ones.

###### 

Characteristics of subjects categorized by UACR quartiles.

  Variables                      UACR (mg/g)         *P* value                                                                  
  ------------------------------ ------------------- ------------------- --------------------------- -------------------------- ---------
  Age (years)                    52.5 ± 10.5         53.8 ± 10.0         56.5 ± 13.2                 58.2 ± 13.7                0.009
  Female, *n* (%)                23 (22.5)           23 (41.1)           39 (48.8)                   40 (50.6)                  \<0.001
  Smoking, *n* (%)               34 (33.3)           13 (23.2)           15 (18.8)                   15 (19.0)                  0.068
  Hypertension, *n* (%)          28 (27.5)           17 (30.4)           27 (33.8)                   47 (59.5)                  \<0.001
  Carotid plaque, *n* (%)        13 (12.7)           9 (16.1)            14 (17.5)                   14 (17.7)                  0.774
  Duration of diabetes (years)   5 (1--9)            7 (1--10)           6 (1--10)                   6 (1--12)                  0.419
  SBP (mmHg)                     129.4 ± 15.5        134.4 ± 15.5        133.2 ± 18.0                139.5 ± 21.0               0.003
  DBP (mmHg)                     81.3 ± 9.2          79.7 ± 10.7         80.6 ± 10.3                 82.1 ± 12.9                0.899
  BMI (kg/m^2^)                  24.7 ± 3.4          24.8 ± 4.0          24.4 ± 4.3                  24.5 ± 4.2                 0.923
  Obesity, *n* (%)               12 (11.8)           11 (19.6)           14 (17.5)                   10 (12.7)                  0.469
                                                                                                                                
  *Medication history*                                                                                                          
  ACEI/ARB use, *n* (%)          15 (14.7)           10 (17.9)           17 (21.3)                   27 (34.2)                  0.014
  Statin use, *n* (%)            45 (44.1)           24 (42.9)           27 (33.8)                   36 (45.6)                  0.416
  CCB use, *n* (%)               11 (10.8)           8 (14.3)            8 (10.3)                    14 (17.7)                  0.435
  *β*-Blocker, *n* (%)           5 (4.9)             5 (8.9)             4 (5.0)                     2 (2.5)                    0.422
                                                                                                                                
  *Laboratory values*                                                                                                           
  HbA1c (%)                      7.6 (6.4--9.8)      7.9 (6.2--10.1)     9.7 (7.8--11.1)             9.2 (7.2--10.8)            \<0.001
  HOMA-IR                        1.65 (0.71--3.08)   1.24 (0.70--2.90)   1.50 (0.74--3.83)           1.35 (0.60--2.46)          0.643
  FPG (mmol/L)                   6.6 (5.3--8.3)      6.9 (4.9--8.7)      7.8 (6.0--9.9)              6.5 (5.2--8.5)             0.026
  Anemia, *n* (%)                7 (6.9)             3 (5.4)             6 (7.5)                     13 (16.5)                  0.074
  CHOL (mmol/L)                  4.83 ± 1.03         4.96 ± 1.20         4.74 ± 0.99                 4.75 ± 1.06                0.638
  LDL-c (mmol/L)                 3.07 ± 0.82         3.13 ± 1.03         3.02 ± 0.73                 2.92 ± 0.82                0.492
  HDL-c (mmol/L)                 1.04 ± 0.29         1.01 ± 0.22         1.06 ± 0.31                 1.06 ± 0.27                0.699
  TG (mmol/L)                    1.26 (0.95--1.95)   1.33 (1.04--2.13)   1.28 (0.93--1.80)           1.44 (1.09--2.03)          0.445
  ALB (g/L)                      40.3 ± 3.3          39.3 ± 3.3          37.9 ± 4.8                  37.7 ± 4.6                 \<0.001
  P (mmol/L)                     1.26 ± 0.23         1.29 ± 0.21         1.26 ± 0.20                 1.26 ± 0.23                0.882
  Na (mmol/L)                    140.9 ± 2.4         140.4 ± 3.5         140.5 ± 2.4                 139.6 ± 4.0                0.054
  Cl (mmol/L)                    104.1 ± 3.2         103.8 ± 3.7         103.2 ± 2.9                 103.1 ± 4.4                0.201
  UREA (mmol/L)                  5.1 (4.5--6.0)      5.5 (4.2--6.2)      5.0 (4.0--6.0)              4.8 (3.9--5.7)             0.550
  UA (*μ*mol/L)                  367.4 ± 91.5        347.6 ± 98.3        334.7 ± 96.9                333.2 ± 108.6              0.068
  eGFR (mL·min^−1^·1.73 m^−2^)   96.0 ± 20.4         100.6 ± 27.4        107.5 ± 31.6                101.2 ± 36.0               0.164
                                                                                                                                
  *Echocardiography*                                                                                                            
  EF (%)                         68.4 (64.0--72.0)   69.9 (64.2--72.1)   67.0 (64.7--72.7)           67.0 (64.0--71.0)          0.510
  AO (mm)                        25.9 ± 3.0          25.1 ± 4.0          25.9 ± 3.5                  25.1 ± 3.4                 0.216
  LA (mm)                        33.0 ± 3.6          30.5 ± 4.1          29.8 ± 3.8                  31.1 ± 4.6                 0.193
  LVIDd (mm)                     42.7 ± 3.9          42.7 ± 4.6          41.5 ± 4.4                  41.5 ± 4.4                 0.108
  LVIDs (mm)                     26.5 ± 3.2          26.2 ± 3.0          25.9 ± 3.7                  26.2 ± 3.9                 0.777
  IVSd (mm)                      10.5 ± 1.3          10.6 ± 1.6          10.5 ± 1.7                  11.3 ± 1.8                 0.008
  LVPWd (mm)                     9.8 ± 1.3           9.9 ± 1.5           9.9 ± 1.4                   10.5 ± 1.6                 0.003
  RWT                            0.46 ± 0.07         0.47 ± 0.10         0.48 ± 0.09                 0.51 ± 0.10                0.001
  LVMI (g/m^2,7^)                36.4 ± 8.0          38.3 ± 8.7          37.2 ± 8.1                  41.7 ± 11.5                0.003
  E/A                            0.82 (0.74--1.19)   0.81 (0.73--1.16)   ^a^(79) 0.80 (0.67--1.14)   \(77\) 0.73 (0.65--0.88)   0.008
  LVH, *n* (%)                   11 (10.8)           9 (16.1)            13 (16.3)                   29 (36.7)                  \<0.001

LVIDd = left ventricular internal dimension diastole; LVIDs = left ventricular internal systole; IVSd = interventricular septal dimension; LVPWd = left ventricular posterior wall dimension. ^a^The remaining valid data regardless of the missing ones.

###### 

Univariate and multiple linear regression analysis to include log~2~ UACR for other clinical parameters.

  Explanatory variable   Univariate regression   Multiple regression                              
  ---------------------- ----------------------- --------------------- --------- -------- ------- ---------
  HbA1c (%)              0.085                   0.022                 \<0.001   0.090    0.021   \<0.001
  Hypertension           0.527                   0.107                 \<0.001   0.498    0.131   \<0.001
  ALB (g/L)              −0.052                  0.012                 \<0.001   −0.037   0.012   0.003
  Age (years)            0.018                   0.004                 \<0.001   0.005    0.004   0.251
  Gender (female)        0.145                   0.032                 \<0.001   0.238    0.116   0.041
  Smoking                −0.331                  0.124                 0.008     −0.211   0.127   0.097
  ACEI/ARB use           0.433                   0.128                 0.001     0.040    0.149   0.789

###### 

Multinomial logistic regression analysis to include log~2~ UACR for LVH.

                       *B*     SE      Wald     df   *P*       OR      95% CI
  -------------------- ------- ------- -------- ---- --------- ------- ---------------
  Gender (female)      1.373   0.359   14.591   1    \<0.001   3.946   1.951--7.981
  Age (years)          0.058   0.016   13.506   1    \<0.001   1.059   1.027--1.093
  Hypertension         1.174   0.355   10.963   1    0.001     3.236   1.615--6.486
  Obesity              1.742   0.437   15.869   1    \<0.001   5.708   2.423--13.447
  Log~2~ UACR (mg/g)   0.417   0.185   5.064    1    0.024     1.517   1.055--2.182

###### 

OR (95% CI) of left ventricular hypertrophy according to UACR.

               UACR (mg/g)         Continuous variables log~2~ UACR (mg/g)   
  ------------ ------------------- ----------------------------------------- -------------------------------
  *N*          255                 62                                        317
  Unadjusted   1.000 (reference)   4.725 (2.635--8.475), \<0.001             2.023 (1.493--2.740), \<0.001
  Model 1      1.000 (reference)   3.413 (1.753--6.644), \<0.001             1.663 (1.161--2.382), 0.006
  Model 2      1.000 (reference)   3.162 (1.593--6.274), 0.001               1.529 (1.062--2.202), 0.022
  Model 3      1.000 (reference)   3.104 (1.557--6.188), 0.001               1.511 (1.047--2.180), 0.028

Values are OR (95% CI) and *P* value; model 1: adjusted for age, gender, and obesity; model 2: further adjusted for hypertension, carotid plaque, and duration of diabetes; model 3: further adjusted for smoking, the use of ACEI or ARB, and statin medication.

[^1]: Academic Editor: Roberto Cangemi
